Current Status of CAR-T Cell Therapy in Multiple Myeloma
Current Status of CAR-T Cell Therapy in Multiple Myeloma
About this item
Full title
Author / Creator
Publisher
Aviano: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Aviano: MDPI AG
Subjects
More information
Scope and Contents
Contents
Current data on CAR-T cell-based therapy is really promising in multiple myeloma, especially in terms of response. In heavily pretreated patients, who have already received proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, current trials report an overall response rate ranging from 81 to 97% and 45 to 67% of complete remissio...
Alternative Titles
Full title
Current Status of CAR-T Cell Therapy in Multiple Myeloma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d265ed9f333140bd87ceb70041da0f8b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d265ed9f333140bd87ceb70041da0f8b
Other Identifiers
ISSN
2673-6357
E-ISSN
2673-6357
DOI
10.3390/hemato2040043
